Bayer and Johnson & Johnson are beginning two more late-stage trials of the blood thinner Xarelto, or rivaroxaban, after failing to get the FDA's OK for the treatment of patients with acute coronary syndrome. One trial involves patients with chronic heart failure and significant coronary artery disease. The other will involve patients with nonvalvular atrial fibrillation.

Full Story:
PharmaTimes (U.K.)

Related Summaries